Isis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Biogen Ma Inc.

Thomas P Condon

C Frank Bennett

Shin Cheng Flournoy

Susan M Freier

Lex M Cowsert

Kenneth W Dobie

Hong Zhang

Ravi Jain

Don W Cleveland

Richard Alan Smith

Jordan S Pober

Weillie Ma

Priyam Singh

Tracy Cole

Timothy Vickers

Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.

Antisense modulation of superoxide dismutase 1, soluble expression

Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.

Methods for slowing familial ALS disease progression

Compositions and methods are provided for modulating the expression of integrin &agr;4. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin &agr;4 are preferred. Methods of using these compounds for modulating integrin &agr;4 expression and for treatment of diseases associated with expression of integrin &agr;4 are also provided.

Antisense modulation of integrin &agr;4 expression

Antisense compounds, compositions and methods are provided for modulating the expression of ADAM10. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ADAM10. Methods of using these compounds for modulation of ADAM10 expression and for treatment of diseases associated with expression of ADAM10 are provided.

Antisense modulation of ADAM10 expression

The present invention provides compositions and methods for detecting and modulating levels of intercellular adhesion molecule-1 (ICAM-1) proteins, including human ICAM-1.

Enhanced antisense modulation of ICAM-1

Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a nucleic acid encoding a lymphocyte function associated antigen 3 (LFA-3; also known as CD58) protein are provided.

Antisense modulation of LFA-3

Compositions and methods are provided for modulating the expression of integrin .alpha.4. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin .alpha.4 are preferred. Methods of using these compounds for modulating integrin .alpha.4 expression and for treatment of diseases associated with expression of integrin .alpha.4 are also provided.

Antisense inhibition of integrin .alpha.4 expression

Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a nucleic acid encoding a platelet endothelial cell adhesion molecule-1 (PECAM-1; also known as CD31 antigen or endoCAM) protein are provided.

Growing community of inventors

Singapore, Singapore

Thomas P Condon